1. Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given treatment with either daptomycin or ceftriaxone.
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

2. Figure 3 Plots of Hill-type pharmacokinetic-pharmacodynamic models for the probability of clinical response (A) and microbiological success (B) versus the free-drug ratio of area under the serum concentration-time curve to MIC (AUC:MIC ratio) in patients with community-acquired pneumonia. AUC:MIC ratios for individual patients are plotted on the X-axis, and the group's probability of clinical success is plotted on the Y-axis, with random jitter shown for graphical clarity [11].
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

3. Figure 2 Plot of a logistic regression pharmacokinetic-pharmacodynamic model for the probability of clinical success versus the ratio of peak plasma concentration to MIC (peak/MIC ratio). Breakpoints for the exposure measures indicate the value for which there is a significantly increased probability of successful outcome, as determined by classification and regression tree analysis. Shown are the probability curves for successful clinical response, including peak/MIC ratio and 3 infection sites. The pulmonary infection site included patients with community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute bacterial sinusitis. Reprinted from [6], with permission from the American Medical Association. Copyright ©1998, American Medical Association. All rights reserved.
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

4. Table 2 Clinical response rate in adult patients with acute exacerbations of chronic bronchitis associated with Streptococcus pneumoniae, according to treatment [4].
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

5. Figure 1 Plot of a Hill-type pharmacokinetic-pharmacodynamic model for the percentage probability of clinical success versus the ratio of the area under the serum concentration-time curve (AUC) to MIC (AUIC mp ) in patients with acute exacerbations of chronic bronchitis. AUC:MIC values for individual patients are plotted on the X-axis, and the group's percentage probability of clinical success is plotted on the Y-axis, with random jitter shown for graphical clarity. Reprinted from [5], with permission from J. J. Schentag and Oxford University Press.
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

6. Figure 4 Schematic depicting the current paradigm of clinical trial design for community-acquired respiratory tract infections. Note that the differences between treatment regimens are not captured during the test-of-cure visit interval.
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

7. Table 1 Bacteriological response rate in children with acute otitis media, according to faropenem dose, in a double-tap study [3].
From: Use of Pharmacokinetics and Pharmacodynamics in a Failure Analysis of Community-Acquired Pneumonia: Implications for Future Clinical Trial Study Design
Clin Infect Dis. 2008;47(Supplement_3):S225-S231. doi: /591427
Clin Infect Dis | © 2008 by the Infectious Diseases Society of America